Navigation Links
XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
Date:5/13/2008

he in-stent late loss for CUSTOM III at six-month follow-up was 0.17 mm, the in-stent binary restenosis rate was 4.4 percent, and the neointimal hyperplasia (NIH) volume was 3.8 percent.

"The CUSTOM III results are very promising and demonstrate the safety of in situ customization for treatment of simple and complex lesions. The IVUS and angiographic results confirm the efficacy of the Custom NX stent, and the Biolimus A9(R) and PLA formulation," said Bernard De Bruyne, M.D., Ph.D., of the OLV Clinic in Aalst, Belgium, and Principal Investigator for the CUSTOM III clinical trial.

"Given the complexity of the patient population from CUSTOM III, we are excited about the results, which are consistent with the outcomes observed from the CUSTOM I and CUSTOM II trials," said Gregory D. Casciaro, XTENT's President and CEO. "We continue to be pleased with the safety profile and efficacy data of Custom NX in today's real-world patients."

About the Custom NX(R) DES System

Custom NX is designed to enable a more personalized approach to the treatment of arterial disease based on each patient's individual lesion characteristics. The Custom NX system allows physicians to customize the length and diameter of the stent at the site of the lesion. The system features a proprietary modular stent design that consists of multiple 6 mm cobalt chromium segments coated with Biolimus A9(R) and PLA, a biodegradable drug carrier. The Custom NX delivery system enables separation at each 6 mm segment and allows for the placement of up to 60 mm of stent. The Custom NX DES System has not been approved for sale by any regulatory authority.

CUSTOM III Webcast and Slide Presentation

As previously announced, XTENT will host a teleconference and slide presentation to review the CUSTOM III data today at 1:00 p.m. EDT (7:00 p.m. CEST). To participate in the conference call, please dial 877-591-4957 (from the U.S.) or 719-325-4895 (international). The webcast and
'/>"/>

SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week
2. XTENT Announces First Quarter 2008 Financial Results
3. Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis
4. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
5. XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007
6. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
7. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
8. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
9. CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic
10. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... FLINT, Mich. , Aug. 31, 2015  Diplomat Pharmacy, ... pharmacy, has announced that Phil Hagerman , Chairman & ... four upcoming investor conferences. Mr. Hagerman and ... 2015 Healthcare Conference in Boston on ... Mr. Hagerman and Mr. Whelan are also scheduled to participate ...
(Date:8/31/2015)... 2015 BioLight Life ... ("BioLight" or the "Company"), a firm that invests ... and cancer diagnostics, today announced that its cancer ... several new genetic markers with high potential to ... with bisphosphonate drugs and was able to repeat ...
(Date:8/31/2015)... , Aug. 31, 2015  Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today it has completed enrollment of ... Review Committee (DRC) earlier this year, into the ... a first-in-class innate defense regulator (IDR) and is ...
Breaking Medicine Technology:Diplomat to Participate in Upcoming Investor Conferences 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6
(Date:8/31/2015)... ... August 31, 2015 , ... ... management device that could effectively deliver oxygen with a lower risk of failure," ... better way, I invented the Adam Device." , The Adam Device offers a ...
(Date:8/31/2015)... Tennessee (PRWEB) , ... August ... ... of Lifestyle Medicine (ACLM), the nation’s medical professional association for physicians and ... in conjunction with the Lifestyle Medicine Foundation, announced today the establishment of ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... MeYou ... recently enhanced its mobile walking app, Walkadoo , by including an in-app step ... goals that adapt to each person’s walking habits. Rather than broadly assign every Walkadoo ...
(Date:8/31/2015)... ... 2015 , ... There’s big news for ZendyHealth , a Los Angeles-based ... Consumer driven health plans (CDHPs) are a growing phenomenon, and ZendyHealth has brought on ... company, and another to answer customers’ questions directly. , John Young, CEO of Consumerdriven, ...
(Date:8/31/2015)... ... 31, 2015 , ... The Brooks Group, a global sales ... department devoted to helping organizations identify and keep the best talent both inside ... Brooks Group believes in offering a solution that goes beyond simply providing assessments ...
Breaking Medicine News(10 mins):Health News:InventHelp® Client's Invents Medical Device to Restore Respiratory Function (BGF-905) 2Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 2Health News:Nominations Sought for Awards Recognizing Exemplary Contribution to the Field of Lifestyle Medicine 3Health News:Walkadoo™ Walking Program Now Includes In-app Step Tracker 2Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 2Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 3Health News:The Brooks Group Introduces Talent Management Division 2Health News:The Brooks Group Introduces Talent Management Division 3
... question results of small Polish study , , TUESDAY, Jan. ... left main coronary artery appeared to give better short-term results ... experts cast some doubt on the clinical value of the ... University of Silesia, compared results of surgery versus stenting in ...
... Educational teleconference on medical therapies to feature Mayo Clinic ... ... 29 Crohn,s disease and ulcerative,colitis patients, caregivers, and healthcare professionals ... Medications?" This,free, live, interactive teleconference through the Crohn,s & Colitis,Foundation will ...
... confused with ... at least one other drug, ROCKVILLE, Md., Jan. 29 ... (USP),revealed that more than 1,400 commonly used drugs are involved in errors,linked ... the MEDMARX report, 1.4% of the errors resulted in patient harm,including seven ...
... Arcadian Health Plan, Inc., a,leading provider of ... its benefits for 2008 and expanded into the,state ... successful rollouts in,Oklahoma, Georgia, South Carolina and Maine., ... premiums, free annual,physicals and flu shots, dental benefits, ...
... Plan, Inc.,a leading provider of Medicare Advantage health plans ... expanded into the,state of Oklahoma. This comes on the ... Maine., Highlights of these plans include $0 premiums ... benefits, and an ever-expanding,provider and hospital network., "We,ve ...
... in Homes and Cars, GENEVA, Jan. 29 It,s ... world,s youth - breathe air polluted,by tobacco smoke. People who ... others to a dangerous mix of toxins including nicotine, carbon,monoxide, ... children to chronic health risks:, -- Increases a ...
Cached Medicine News:Health News:Stents Slightly Better Than Bypass for Blocked Left Coronary Artery 2Health News:Stents Slightly Better Than Bypass for Blocked Left Coronary Artery 3Health News:Interactive Teleconference on Inflammatory Bowel Disease for Patients, Caregivers, and Healthcare Professionals 2Health News:U.S. Pharmacopeia 8th Annual MEDMARX(R) Report Indicates Look-Alike/Sound-Alike Drugs Lead to Thousands of Medication Errors Nationwide 2Health News:U.S. Pharmacopeia 8th Annual MEDMARX(R) Report Indicates Look-Alike/Sound-Alike Drugs Lead to Thousands of Medication Errors Nationwide 3Health News:Bright Options for Medicare Beneficiaries in Louisiana 2Health News:Expanded Options for Medicare Beneficiaries in Oklahoma 2Health News:Global Initiative To Protect Children From Secondhand Smoke 2Health News:Global Initiative To Protect Children From Secondhand Smoke 3
Control Plasma for Assays of Unfractionated Heparins (UH) using Anti-Xa Methodon STA© Analyzers....
... Normal and Abnormal ... Assays of vWF, D-dimer ... on STA© Analyzers. For ... vWF (#0518),STA© LIATEST© D-DI ...
CRP high sensitivity calibrator series...
Inquire...
Medicine Products: